MAFLD and Liver Cancer Risk: The Elastography Connection
Why metabolic fatty liver disease is now a leading cause of hepatocellular carcinoma — and how elastography fits into the surveillance pathway for at-risk patients.
Hepatocellular carcinoma (HCC) — the most common form of primary liver cancer — has historically been associated with viral hepatitis and alcohol-related cirrhosis. That picture is changing. MAFLD is now one of the fastest-growing causes of HCC in Australia and globally, and elastography plays a central role in identifying who needs ongoing surveillance.
The MAFLD–HCC link
MAFLD progresses through stages: simple steatosis, steatohepatitis (MASH), fibrosis, cirrhosis, and in some patients, HCC. The risk of HCC accelerates significantly once cirrhosis develops, but — uniquely among liver diseases — MAFLD can produce HCC in non-cirrhotic livers too. Roughly 20–30% of MAFLD-associated HCC cases occur without cirrhosis, which complicates surveillance strategies.
Australian population trends — high rates of type 2 diabetes, obesity, and metabolic syndrome — mean that MAFLD-associated HCC is expected to continue growing as a proportion of new liver cancer diagnoses.
Where elastography fits in surveillance
International guidelines (EASL, AASLD, GESA) recommend six-monthly HCC surveillance with ultrasound (with or without alpha-fetoprotein) for patients with cirrhosis from any cause. The first practical question is therefore: who has cirrhosis, and who doesn't?
Elastography is the most accessible non-invasive way to identify cirrhosis. A kPa value above 12–15 (depending on aetiology) suggests F3–F4 fibrosis and triggers consideration of surveillance imaging. For patients with intermediate kPa values, repeat elastography at 12-monthly intervals helps track progression.
What this means in primary care
GPs managing MAFLD patients with type 2 diabetes, obesity, or metabolic syndrome can use FIB-4 as a first-line filter, then escalate to elastography for indeterminate or high-risk results. Patients with confirmed cirrhosis should be referred for specialist hepatology input and HCC surveillance imaging.
Patients with significant fibrosis but no cirrhosis sit in a more ambiguous space — surveillance is not universally indicated, but ongoing fibrosis monitoring and metabolic management are essential.